Cytomegalovirus (CMV) infection is one of the major causes of morbidity in patients undergoing allogeneic stem cell transplantation (alloSCT). The incidences of CMV antigenemia and CMV disease in 43 patients who received allogeneic bone marrow transplantation (BMT) using a reduced-intensity conditioning (RIC) regimen, which mainly consisted of fludarabine, busulfan and total body irradiation, were compared with those in 68 patients who received a myeloablative conditioning (MAC) regimen, and risk factors for CMV antigenemia and CMV disease were identified.
Introduction
Cytomegalovirus (CMV) infection is one of the major causes of morbidity in patients undergoing allogeneic stem cell transplantation (allo-SCT). Preemptive antiviral therapy has been shown to reduce the risk of CMV disease [1] [2] [3] . Major risk factors for CMV infection are serological status of the donor and recipient, graft-versus-host disease (GVHD), corticosteroid administration and T-cell depletion [1, 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Recently, reduced-intensity conditioning (RIC) regimens have been developed for patients who had been considered ineligible for SCT using a myeloablative conditioning (MAC) regimen because of advanced age or medical contraindications [14, 15] . Although many studies have shown that infection before engraftment was reduced in patients undergoing RIC due to a shorter neutropenic period and less severe mucositis [16] [17] [18] [19] , risks of CMV infection have not been substantially reduced after RIC-SCT [1, 7, 8, [10] [11] [12] . Again, we need to consider the difference in CMV infection depending on the RIC regimen because various RIC protocols have been developed and the toxicity profile might vary from one protocol to another due to variability in the degree of immunosuppression or myeloablation [8, 10, 11, 14, 15] . We should also consider the difference in CMV infection depending on the stem cell source [8, 20] .
The present study was a retrospective analysis to compare the incidence of CMV infection in 43 consecutive patients who received bone marrow transplantation (BMT) using an RIC regimen, which mainly consisted of fludarabine (FLU), busulfan (BU) and total body irradiation (TBI) (FLU/BU/TBI), in our institution with that in 68 patients who received MAC-BMT during the same period. The risk factors for CMV antigenemia and development of CMV disease were also investigated.
Patients and methods

Patients
One hundred eleven consecutive adult patients with advanced hematological diseases who received allogeneic BMT using RIC regimens (43 patients) or MAC regimens (68 patients) between September 2000 and March 2007 at Hokkaido University Hospital were analyzed for CMV infections. Twenty-eight patients received an RIC regimen due to advanced age (>50 years) and ten received an RIC regimen due to prior autologous transplantation (five patients overlapped with the patients of advanced age). A difference in the risk of CMV infection depending on stem cell source has been reported [8, 20] , and we cannot use PBSC from an unrelated donor (PBSC can be used only from related donors.) in Japan. Moreover, it has been reported that cord blood showed differences in the incidences of infections and kinetics of immunological recovery from other stem cell sources. Therefore, we analyzed only patients who received BMT. Patients who had already received allogeneic SCT were excluded from this study.
Conditioning regimens
In the RIC group, 38 (88.4%) of the patients received a conditioning regimen of FLU/BU/TBI, which consisted of FLU at a dose of 30 Prednisolone was administered for patients who developed grade ≥2 acute GVHD (aGVHD) at a dose of 0.5-1.0 mg/kg daily according to a physician's decision. The dose of prednisolone administered was lower than the dose used in other countries because of the lower incidence of critical aGVHD in Japan [23] .
CMV surveillance and treatment Pretransplant serum samples from all patients and donors were tested for serologic evidence of past infection with CMV by an enzyme-linked immunosorbent assay or complement fixation test. When a patient and a donor were both negative for CMV, patients received CMV-negative blood products. When a patient or a donor was positive for CMV, the patient was given unscreened blood products. Surveillance CMV enteritis was diagnosed when gastrointestinal signs or symptoms occurred, and evidence of CMV in the gastrointestinal tract was diagnosed by culture, immunohistochemistry, or in situ hybridization from biopsy specimens [10] . CMV hepatitis was diagnosed when liver dysfunction occurred, and evidence of CMV in liver tissue was diagnosed by culture, immunohistochemistry, or in situ hybridization from biopsy specimens. AGVHD and chronic GVHD (cGVHD) were graded by standard criteria [25, 26] . Overall survival (OS) was calculated from the day of SCT until death or last follow-up.
End points and statistical analysis
The aims of this study were to compare the incidences of CMV antigenemia and the incidences of CMV disease in patients undergoing RIC and MAC regimens and to identify risk factors. Univariate analyses were performed using the χ 2 test and Fisher's exact test, as appropriate. The probabilities of CMV antigenemia, CMV disease, OS and PFS were estimated using the Kaplan-Meier method. Effects of the conditioning regimens on survival and CMV infections were studied using the logrank test.
Multivariate logistic regression models were used to analyze the influence of selected variables with the forward stepwise method on the risk of CMV antigenemia and CMV disease. All P-values were two-sided and a P-value of 0.05 was used as the cutoff for statistical significance.
Results
Patient and transplantation characteristics
Patient and transplantation characteristics are summarized in Table 1 . Median age, GVHD prophylaxis, underlying disease, prior autologous transplantation and months from diagnosis to transplantation were significantly different between RIC patients and MAC patients. CMV serostatus was not different between RIC patients and MAC patients.
Transplantation outcomes
Transplantation outcomes are summarized in Risk factors for CMV antigenemia and CMV disease (Table 3) Univariate analysis showed that CMV seropositivity of patients at SCT, any grade of aGVHD, gastrointestinal aGVHD and corticosteroid administration were risk factors for CMV antigenemia. CMV seropositivity of the patients and corticosteroid administration remained significant in multivariate analysis.
Analyses of risk factors for CMV disease were also performed. In univariate analysis, 
Discussion
In this study, we analyzed the incidence and characteristics of CMV infections in patients who received allogeneic BMT after an RIC regimen of FLU/BU/TBI and we compared the incidences of CMV antigenemia and CMV disease in RIC patients and MAC patients.
CMV antigenemia developed in 64% of the RIC patients, a higher incidence than the incidence found in other studies (about 40-50%) [1, 8, 10, 11, 13] . It has been reported that the incidence of CMV activation was not reduced in RIC patients [1, 7, 8, [10] [11] [12] , and reported risk factors for CMV infection in RIC patients include CMV serostatus, HLA-matched unrelated donor, advanced age of donor, grade II-IV aGVHD, corticosteroid administration, Campath-1H and/or anti-thymocyte globulin in the conditioning regimen and BM as a stem cell source [1, 2, [4] [5] [6] [8] [9] [10] [11] [12] [13] 27, 28] . In our study, all patients received BM as a stem cell source, and the number of high-risk patients of CMV serostatus in our study was larger than that in other studies, which might explain the higher incidence of CMV antigenemia. Multivariate analysis in this study confirmed CMV serostatus and corticosteroid administration as significant risk factors for CMV antigenemia.
Although the incidence of CMV antigenemia was not decreased in RIC patients, CMV disease was decreased in RIC patients. The incidence of CMV disease in this study was not increased compared to that in other studies and it was significantly decreased in RIC patients compared with that in MAC patients. In the present study, grade II-IV aGVHD and grade 3-4 diarrhea before engraftment were revealed by multivariate analysis to be significant risk factors for development of CMV disease.
The incidences of grade II-IV aGVHD and the median dose of corticosteroid for GVHD in RIC patients and MAC patients were the same. The median duration of corticosteroid therapy was longer in RIC patients with marginal significance.
Therefore, we do not think that the incidence of grade II-IV aGVHD and the intensity and the duration of immunosuppressants mainly contribute to the higher incidence of CMV disease in MAC patients. This is the first study to show an increased risk of CMV disease among patients with severe diarrhea due to the conditioning regimen, which reflected mucosal injury of the gut. Almost all of the CMV diseases that occurred in our patients were CMV enteritis; therefore, diarrhea was determined to be a risk factor for CMV disease. The incidence of CMV antigenemia was not different between patients with grade 3-4 diarrhea and patients without grade 3-4 diarrhea. Also, the incidences of grade II-IV aGVHD and gastrointestinal aGVHD were not different between patients with grade 3-4 diarrhea and patients without grade 3-4 diarrhea (data not shown). These findings suggested that severe diarrhea affected the incidence of CMV disease directly, not via aGVHD. CMV disease occurred in 46.7% of the patients who developed both grade 3-4 diarrhea and grade II-IV aGVHD, but CMV disease occurred in only 12.5% of the patients who developed grade II-IV aGVHD without grade 3-4 diarrhea. CMV disease occurred in only one patient who had no grade II-IV aGVHD. These results suggested that immunosuppression in the whole body due to aGVHD (and corticosteroid) was most important for "CMV reactivation"
but that mucosal injury of the gut was also necessary for development of "CMV disease". It has been reported that mucosal immunity of the gut is an important defensive system against pathogens including CMV and that immunoglobulin, macrophages and T-lymphocytes play a pivotal role in this local immunity. Therefore, impairment of mucosal immunity of the gut due to the conditioning regimen might have influenced the incidence of CMV enteritis in our patients [29] [30] [31] . Risk of severe diarrhea before engraftment may be complicated with our MAC regimen, which mainly included VP-16 [22] . We should consider the increased risk for development of CMV disease in patients with severe diarrhea before engraftment and in these patients who develop grade II-IV aGVHD. Although our analysis has limitations due to its retrospective fashion and small sample size, patients who received an RIC regimen showed a lower risk of CMV disease, and mucosal injury of the gut was determined to be a significant risk factor for development of CMV disease. Further studies are needed to confirm these findings.
Titles and legends to figures Figure 1 Cumulative incidences of CMV antigenemia (a) and CMV disease (b). Figure 2 Cumulative incidence of CMV disease according to the combination of two risk factors: grade II-IV aGVHD and grade 3-4 diarrhea before engraftment.
Group A included patients who had both grade II-IV aGVHD and grade 3-4 diarrhea before engraftment (n=15). Group B included patients who had grade II-IV aGVHD but did not develop grade 3-4 diarrhea before engraftment (n=32). Group C included patients who did not develop grade II-IV aGVHD (n=52). 
